Novo Nordisk A/S
NVO55.620USD
Today
+1.37%
5 Days
+2.47%
1 Month
+6.12%
6 Months
-27.91%
Year to Date
-35.34%
1 Year
-59.40%
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
Score Analysis
Analyst Rating
Company Highlights
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
News
Novo Nordisk to Cut 9,000 Jobs and Lowers Profit Growth Forecast; Analysts See Positive Signals
TradingKey - On Wednesday, September 10, Danish pharmaceutical company Novo Nordisk (NVO), known for its obesity drugs Wegovy and Ozempic, announced a restructuring plan involving global job cuts of 9,000 employees and a third downward revision of its profit growth forecast this year. This move mark
Cut to Grow, Novo Nordisk Announces 11% Global Layoffs, Third Profit Forecast Cut This Year
TradingKey - Obesity drug giant Novo Nordisk (NVO.US) announced on Wednesday a major restructuring plan, including 9,000 global job cuts, and delivered its third downward revision to its full-year profit growth guidance in 2025. However, due to its undervalued stock and hopes for cost savings and
Should You Buy Novo Nordisk Stock Now or Wait?
In this video, I will talk about the recent updates regarding Novo Nordisk (NYSE: NVO). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Aug. 28, 2025. The video was published on Sept. 1, 2025.Where to i
Novo Nordisk woes prompt Denmark to slash country's 2025 growth forecast
Aug 29 (Reuters) - Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk NOVOb.CO and tariffs on Danish goods exported to the U.S., the country's economy ministry said on Friday.
Has Novo Nordisk Hit Bottom? 50% Price Cut and MASH Exclusivity Spark Growth Momentum
TradingKey - Amid competition from Eli Lilly and generic drugmakers, obesity drug leader Novo Nordisk (NVO) has seen its stock nearly halved year-to-date. After reporting a below-expected Q2 earnings, Novo Nordisk’s shares appear to be recovering from a bottom, driven by a 50% price reduction for
Eli Lilly Sinks 12% Pre-Market on Disappointing Obesity Pill Data
TradingKey - Eli Lilly (LLY), the pharmaceutical giant, experienced a significant 12% drop in its pre-market stock price on Thursday, marking the largest single-day decline for the company in 26 years.
Financial Indicators
EPS
Total revenue
Company
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Related Instruments
